ScaleReady awards a $300,000 G-Rex® Grant to A2 Biotherapeutics, Inc.
ScaleReady has awarded a $300,000 G-Rex® Grant to A2 Biotherapeutics to support process development and evaluation of G-Rex for manufacturing cell therapies. The grant enables A2 to explore the G-CART process, a standardized workflow for CAR-T drug product manufacturing, developed by Cell Ready.
A2 will evaluate this platform for their proprietary Tmod™ platform, a dual-signal integrator system for cancer cell therapy targeting various solid tumor indications including colorectal, lung, pancreatic, and ovarian cancers. The G-Rex Grant Program, which has awarded nearly 200 grants with over 50 new applications pending, has been extended with millions in additional funding.
ScaleReady ha assegnato un Grant G-Rex® da 300.000 $ a A2 Biotherapeutics per supportare lo sviluppo dei processi e la valutazione della tecnologia G-Rex nella produzione di terapie cellulari. Il finanziamento consente ad A2 di esplorare il processo G-CART, un flusso di lavoro standardizzato per la produzione di farmaci CAR-T, sviluppato da Cell Ready.
A2 valuterà questa piattaforma per la propria piattaforma Tmod™, un sistema integratore a doppio segnale per la terapia cellulare contro vari tumori solidi, tra cui cancro del colon-retto, polmonare, pancreatico e ovarico. Il Programma Grant G-Rex, che ha già assegnato quasi 200 finanziamenti con oltre 50 nuove domande in attesa, è stato esteso con milioni di fondi aggiuntivi.
ScaleReady ha otorgado una Subvención G-Rex® de 300,000 $ a A2 Biotherapeutics para apoyar el desarrollo de procesos y la evaluación de G-Rex en la fabricación de terapias celulares. La subvención permite a A2 explorar el proceso G-CART, un flujo de trabajo estandarizado para la fabricación de productos farmacéuticos CAR-T, desarrollado por Cell Ready.
A2 evaluará esta plataforma para su propia plataforma Tmod™, un sistema integrador de doble señal para terapias celulares contra varios tumores sólidos, incluyendo cáncer colorrectal, de pulmón, páncreas y ovario. El Programa de Subvenciones G-Rex, que ha otorgado casi 200 subvenciones y tiene más de 50 nuevas solicitudes pendientes, se ha extendido con millones en financiamiento adicional.
ScaleReady는 세포 치료제 제조를 위한 공정 개발 및 G-Rex 평가를 지원하기 위해 A2 Biotherapeutics에 30만 달러 규모의 G-Rex® 보조금을 수여했습니다. 이 보조금은 A2가 Cell Ready에서 개발한 CAR-T 약물 제품 제조를 위한 표준화된 작업 흐름인 G-CART 공정을 탐색할 수 있도록 합니다.
A2는 대장암, 폐암, 췌장암, 난소암 등 다양한 고형암 적응증을 겨냥한 이중 신호 통합 시스템인 독자적인 Tmod™ 플랫폼에 대해 이 플랫폼을 평가할 예정입니다. 거의 200건의 보조금을 수여하고 50건 이상의 신규 신청이 대기 중인 G-Rex 보조금 프로그램은 수백만 달러의 추가 자금으로 연장되었습니다.
ScaleReady a attribué une subvention G-Rex® de 300 000 $ à A2 Biotherapeutics pour soutenir le développement des processus et l’évaluation de G-Rex dans la fabrication de thérapies cellulaires. Cette subvention permet à A2 d’explorer le processus G-CART, un flux de travail standardisé pour la fabrication de produits médicamenteux CAR-T, développé par Cell Ready.
A2 évaluera cette plateforme pour sa propre plateforme Tmod™, un système intégrateur à double signal pour la thérapie cellulaire ciblant divers cancers solides, notamment colorectal, du poumon, du pancréas et de l’ovaire. Le programme de subventions G-Rex, qui a déjà attribué près de 200 subventions avec plus de 50 nouvelles demandes en attente, a été prolongé avec plusieurs millions de financements supplémentaires.
ScaleReady hat A2 Biotherapeutics einen G-Rex®-Zuschuss in Höhe von 300.000 $ zugesprochen, um die Prozessentwicklung und Bewertung von G-Rex für die Herstellung von Zelltherapien zu unterstützen. Der Zuschuss ermöglicht es A2, den G-CART-Prozess zu erforschen, einen standardisierten Arbeitsablauf für die Herstellung von CAR-T-Arzneimitteln, der von Cell Ready entwickelt wurde.
A2 wird diese Plattform für seine eigene Tmod™-Plattform evaluieren, ein Dual-Signal-Integratorsystem für die Zelltherapie bei verschiedenen soliden Tumorerkrankungen, einschließlich kolorektalem, Lungen-, Bauchspeicheldrüsen- und Eierstockkrebs. Das G-Rex-Zuschussprogramm, das bereits fast 200 Zuschüsse vergeben hat und über 50 neue Anträge in Bearbeitung hat, wurde mit zusätzlichen Millionen an Fördermitteln verlängert.
- Grant provides $300,000 in valuable resources for process development
- Access to exclusive support from ScaleReady's consortium of G-Rex Grant Partners
- Opportunity to evaluate standardized G-CART process for high-throughput manufacturing
- None.
Insights
ScaleReady's $300,000 grant to A2 Biotherapeutics validates G-Rex technology but represents modest financial impact for Bio-Techne.
This grant represents a strategic move in the cell therapy manufacturing space. The
The technical advantages are significant: G-Rex technology provides a simpler gas exchange mechanism that reduces handling steps and contamination risks compared to conventional systems. For A2's Tmod platform targeting solid tumors (colorectal, lung, pancreatic, and ovarian), manufacturing efficiency is particularly crucial given the complex dual-receptor system that distinguishes between normal cells and cancer cells based on tumor loss of heterozygosity.
Cell therapy manufacturing constraints remain one of the industry's primary bottlenecks, making process development investments like this potentially valuable for accelerating clinical programs. The standardized G-CART workflow and GMP ProPak cytokines (IL-2, IL-7, IL-15) mentioned will likely reduce process variability—a persistent challenge in cell therapy production.
For Bio-Techne (TECH), this represents modest technology validation rather than significant immediate revenue. The program's scale (nearly 200 grants awarded) suggests this is part of a broader technology adoption strategy rather than a one-off partnership.
"We are very impressed by the simplicity and scalability of the G-Rex platform and look forward to exploring its applications in our clinical development programs." says Dr. Agi Hamburger, Chief Operating Officer at A2. "As an early-stage company, the G-Rex Grant provides valuable resources to support the process development and comparability studies."
"We appreciate the opportunity to help A2 Biotherapeutics explore an alternative manufacturing pathway that is distinct from the 'all-in-one' bioreactor approach. We believe a modular and flexible closed approach is necessary for cell therapy developers to set the basis for LEAN manufacturing while establishing phase appropriate production. This is the best way to generate drug product supply that is commensurate with their total patient demand," says John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex.
As part of the G-Rex Grant, A2 will evaluate the G-CART process, a standardized workflow for assembling CAR-T drug product, currently in development at Cell Ready, the world's first and only G-Rex centric contract development and manufacturing organization (CDMO). The G-CART process is designed for high-throughput manufacturing in centralized or point of care models and will be readily adaptable to full end-to-end robotic automation for commercial scale production. The G-CART process will make creative use of novel sub-assemblies to streamline the flow of the drug substance through the final assembly line, including the new GMP ProPak cytokines from Bio-Techne. ProPaks are GMP grade, liquid formulated, process-sized cytokines filled in sterile-weldable bags tailormade for use with the G-Rex device. Various interleukins, including IL-2, IL-7, and IL-15 are available in ProPak form.
A2's CAR-T cell pipeline is based on their proprietary Tmod™ platform. The Tmod platform is a dual-signal integrator system for cancer cell therapy that consists of an activating receptor and an inhibitory receptor (blocker module). It utilizes tumor loss of heterozygosity to clearly distinguish normal cells containing both the activator and blocker antigens from tumor cells expressing the activator antigen, but which have irreversibly lost the blocker antigen. A2's current clinical pipeline consists of CAR-T cell therapies targeting various solid tumor indications including colorectal, lung, pancreatic, and ovarian cancers.
ScaleReady's G-Rex Grant Program is advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to
For more information about the G-Rex® Grant Program, please contact info@scaleready.com.
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time.
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-awards-a-300-000-g-rex-grant-to-a2-biotherapeutics-inc-302435901.html
SOURCE Bio-Techne Corporation
FAQ
What is the value of the G-Rex Grant awarded to A2 Biotherapeutics?
What types of cancer does A2 Biotherapeutics' Tmod platform target?
How many G-Rex Grants has ScaleReady awarded so far?
What is the G-CART process that A2 Biotherapeutics will evaluate?
